Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center.
Adult
Carcinoma, Papillary
/ diagnosis
Disease Progression
Feasibility Studies
Female
Follow-Up Studies
Humans
Incidence
Italy
/ epidemiology
Lymph Nodes
/ diagnostic imaging
Male
Middle Aged
Practice Guidelines as Topic
Risk Factors
Thyroid Gland
/ diagnostic imaging
Thyroid Neoplasms
/ diagnosis
Thyroidectomy
Treatment Outcome
Ultrasonography
/ standards
Watchful Waiting
/ standards
active surveillance
differentiated thyroid cancer
management
microcarcinoma
observation
outcome
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
01 03 2020
01 03 2020
Historique:
received:
18
04
2019
accepted:
16
10
2019
pubmed:
28
10
2019
medline:
11
11
2020
entrez:
26
10
2019
Statut:
ppublish
Résumé
The dramatic rise in the incidence of thyroid cancer over the last 30 years is largely attributable to the increasing diagnosis of papillary microcarcinomas (mPTCs). Current guidelines endorse an observational management approach in properly selected cases. To evaluate the feasibility of active surveillance in mPTC in Italy, its impact on real life, and to identify risk factors of progression. In 2014 we started a prospective-observational study of active surveillance in mPTC patients. Included patients demonstrated a single Thy4 or Thy5 thyroid nodule, with largest diameter ≤1.3 cm, and no suspicious laterocervical lymph nodes by neck ultrasonography. Of 185 eligible subjects, 50.3% (93/185) enrolled in the observational management protocol while the others opted for surgery and were excluded from this analysis. Enrolled patients were followed with neck ultrasound at 6- to 12-month intervals. Disease progression was defined as the appearance of abnormal lymph nodes or nodule enlargement during follow-up. In these cases, patients were directed to surgery. Three patients (3/93, 3%) showed clinical progression and required surgery. Another 19 patients (19/93, 20%) decided to transition to surgical intervention even though there was no evidence of disease progression. All operated patients had excellent response to initial treatment despite the delayed surgery. Within an Italian medical context, active surveillance appears to be a feasible and safe alternative to immediate surgery in healthy mPTC patients. Only 3% of mPTC demonstrated disease progression during a median follow-up of 19 months (range 6-54) and importantly demonstrated excellent outcomes after surgical intervention in a short-term follow-up.
Identifiants
pubmed: 31652318
pii: 5607347
doi: 10.1210/clinem/dgz113
pmc: PMC8105780
pii:
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
JAMA Otolaryngol Head Neck Surg. 2019 Apr 1;145(4):363-370
pubmed: 30703198
Expert Rev Endocrinol Metab. 2018 Mar;13(2):77-85
pubmed: 30058863
Endocr Relat Cancer. 2017 Apr;24(4):197-207
pubmed: 28223365
JAMA Oncol. 2019 Apr 1;5(4):556-564
pubmed: 30543358
Thyroid. 2017 Dec;27(12):1490-1497
pubmed: 29020892
Cancer. 1989 Mar 1;63(5):908-11
pubmed: 2914297
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
N Engl J Med. 2018 Jul 26;379(4):310-312
pubmed: 30044933
Am J Clin Pathol. 2009 Nov;132(5):658-65
pubmed: 19846805
World J Surg. 2010 Jan;34(1):28-35
pubmed: 20020290
Thyroid. 2010 Dec;20(12):1341-9
pubmed: 21034228
World J Surg. 2007 Aug;31(8):1672-6
pubmed: 17571205
JAMA Otolaryngol Head Neck Surg. 2017 Oct 1;143(10):1015-1020
pubmed: 28859191
J Endocrinol Invest. 2014 Jun;37(6):593-9
pubmed: 24789536
Ann Surg Oncol. 2016 Apr;23(4):1361-70
pubmed: 26597365
J Urol. 2018 Dec;200(6):1250-1255
pubmed: 29886089
Thyroid. 2005 Sep;15(9):1041-5
pubmed: 16187912
JAMA. 2017 May 9;317(18):1882-1887
pubmed: 28492905
Diagn Cytopathol. 1996 Jul;15(1):84-9
pubmed: 8807260
World J Surg. 2010 Jun;34(6):1222-31
pubmed: 20066418
J Clin Endocrinol Metab. 1991 Jan;72(1):209-13
pubmed: 1986019
BMJ Open. 2018 Apr 12;8(4):e020298
pubmed: 29654030
N Engl J Med. 2016 Jan 28;374(4):390-2
pubmed: 26816018
Thyroid. 2016 Jan;26(1):150-5
pubmed: 26426735
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Thyroid. 2014 Jan;24(1):27-34
pubmed: 24001104
Thyroid. 2003 Apr;13(4):381-7
pubmed: 12804106
J Clin Oncol. 2016 Oct 20;34(30):3672-3679
pubmed: 27601555